WO2022263927A3 - Plasmalogen derivatives and uses thereof - Google Patents
Plasmalogen derivatives and uses thereof Download PDFInfo
- Publication number
- WO2022263927A3 WO2022263927A3 PCT/IB2022/000336 IB2022000336W WO2022263927A3 WO 2022263927 A3 WO2022263927 A3 WO 2022263927A3 IB 2022000336 W IB2022000336 W IB 2022000336W WO 2022263927 A3 WO2022263927 A3 WO 2022263927A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- diseases
- compounds
- blood
- derivatives
- disorders
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 5
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 208000026350 Inborn Genetic disease Diseases 0.000 abstract 1
- 208000019693 Lung disease Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 208000019229 Spleen disease Diseases 0.000 abstract 1
- 230000008499 blood brain barrier function Effects 0.000 abstract 1
- 210000001218 blood-brain barrier Anatomy 0.000 abstract 1
- 210000004155 blood-retinal barrier Anatomy 0.000 abstract 1
- 230000004378 blood-retinal barrier Effects 0.000 abstract 1
- 239000013078 crystal Substances 0.000 abstract 1
- 208000016361 genetic disease Diseases 0.000 abstract 1
- 208000014951 hematologic disease Diseases 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 208000012268 mitochondrial disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000017520 skin disease Diseases 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 208000027140 splenic disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/113—Esters of phosphoric acids with unsaturated acyclic alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
- C07F9/106—Adducts, complexes, salts of phosphatides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/59—Hydrogenated pyridine rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms
- C07F9/655363—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Provided herein are compounds (e.g., compounds of Formulae (I) and (II)), and pharmaceutically acceptable salts, hydrates, solvates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof, and compositions, methods, uses, and kits thereof. The compounds provided herein include plasmalogens and plasmalogen derivatives. The compounds provided herein may cross the blood-brain barrier and/or blood-retinal barrier or be transported by the Mfsd2a protein. Accordingly, such compounds are useful for the treatment and/or prevention of various diseases and conditions (e.g., liver diseases, neurological diseases, ophthalmic diseases, metabolic disorders, mitochondrial diseases, cardiovascular diseases, infectious diseases, pulmonary diseases, skin diseases, genetic diseases, proliferative diseases, inflammatory diseases, autoimmune diseases, hematological diseases, painful conditions, psychiatric disorders, immune disorders, and spleen diseases).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163212034P | 2021-06-17 | 2021-06-17 | |
US63/212,034 | 2021-06-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2022263927A2 WO2022263927A2 (en) | 2022-12-22 |
WO2022263927A3 true WO2022263927A3 (en) | 2023-03-23 |
Family
ID=82748498
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2022/000336 WO2022263927A2 (en) | 2021-06-17 | 2022-06-16 | Plasmalogen derivatives and uses thereof |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2022263927A2 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007098585A1 (en) * | 2006-02-28 | 2007-09-07 | Phenomenome Discoveries Inc. | Methods for the diagnosis of dementia and other neurological disorders |
WO2013071418A1 (en) * | 2011-11-17 | 2013-05-23 | Phenomenome Discoveries Inc. | Methods for the synthesis of plasmalogens and plasmalogen derivatives, and therapeutic uses thereof |
WO2013071412A1 (en) * | 2011-11-17 | 2013-05-23 | Phenomenome Discoveries Inc. | Methods for the synthesis of 13c labeled plasmalogen |
-
2022
- 2022-06-16 WO PCT/IB2022/000336 patent/WO2022263927A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007098585A1 (en) * | 2006-02-28 | 2007-09-07 | Phenomenome Discoveries Inc. | Methods for the diagnosis of dementia and other neurological disorders |
WO2013071418A1 (en) * | 2011-11-17 | 2013-05-23 | Phenomenome Discoveries Inc. | Methods for the synthesis of plasmalogens and plasmalogen derivatives, and therapeutic uses thereof |
WO2013071412A1 (en) * | 2011-11-17 | 2013-05-23 | Phenomenome Discoveries Inc. | Methods for the synthesis of 13c labeled plasmalogen |
Non-Patent Citations (11)
Title |
---|
AREA-GOMEZ ESTELA ET AL: "Lipidomics study of plasma from patients suggest that ALS and PLS are part of a continuum of motor neuron disorders", SCIENTIFIC REPORTS, vol. 11, no. 1, 30 June 2021 (2021-06-30), XP093000296, Retrieved from the Internet <URL:http://www.nature.com/articles/s41598-021-92112-3> DOI: 10.1038/s41598-021-92112-3 * |
DATABASE CAPLUS [online] Americal Chemical Astracts Service; 1 December 2012 (2012-12-01), TANG CHUAN-HO ET AL: "Phosphorylcholine-containing lipid molecular species profiling in biological tissue using a fast HPLC/QqQ-MS method", XP093000353, retrieved from STN Database accession no. 2012:1409478 * |
DATABASE CAPLUS [online] American Chemical Abstracts Service; 1 October 2008 (2008-10-01), SUN GANG ET AL: "Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometric Analysis of Cellular Glycerophospholipids Enabled by Multiplexed Solvent Dependent Analyte-Matrix Interactions", XP093000357, retrieved from STN Database accession no. 2008:1068778 * |
DATABASE CAPLUS [online] American Chemical Astracts Service; 14 December 2016 (2016-12-14), MAO KAI P ; ET AL: "Unsaturated plasma phospholipids are consistently lower in the patients diagnosed with gestational diabetes mellitus throughout pregnancy: A longitudinal metabolomics study of Chinese pregnant women part 1", XP093000337, retrieved from STN Database accession no. 2017:73589 * |
DATABASE CAPLUS [online] Chemical Astracts; 30 July 2020 (2020-07-30), KARNANI NEERJA ; ET AL: "Maternal docosapentaenoic acid (DPA) for benefit of mother and/or child's mental health", XP093000303, retrieved from STN Database accession no. 2020:1469510 * |
EDDAMIRAYFITAHIA ET AL: "High-Resolution Mass Spectrometry Unravels aBroad Range ofBioactive Lipid Species inOctopus cyanea andLoligo sp. By- products fromSouthwestern Madagascar", 1 January 2018 (2018-01-01), pages 1787 - 1793, XP055983135, Retrieved from the Internet <URL:https://link.springer.com/content/pdf/10.1007/s12649-017-9933-x.pdf> [retrieved on 20221118] * |
HUYNH KEVIN ET AL: "Lipidomic Profiling of Murine Macrophages Treated with Fatty Acids of Varying Chain Length and Saturation Status", METABOLITES, vol. 8, no. 2, 23 April 2018 (2018-04-23), pages 29, XP093000315, DOI: 10.3390/metabo8020029 * |
LANKALAPALLI RAVI S. ET AL: "Synthesis and Antioxidant Properties of an Unnatural Plasmalogen Analogue Bearing a trans O -Vinyl Ether Linkage", ORGANIC LETTERS, vol. 11, no. 13, 2 July 2009 (2009-07-02), US, pages 2784 - 2787, XP055983100, ISSN: 1523-7060, DOI: 10.1021/ol9009078 * |
LAW KAI P ET AL: "Unsaturated plasma phospholipids are consistently lower in the patients diagnosed with gestational diabetes mellitus throughout pregnancy: A longitudinal metabolomics study of Chinese pregnant women part 1", CLINICA CHIMICA ACTA, ELSEVIER BV, AMSTERDAM, NL, vol. 465, 14 December 2016 (2016-12-14), pages 53 - 71, XP029907172, ISSN: 0009-8981, DOI: 10.1016/J.CCA.2016.12.010 * |
LESSIG JACQUELINE ET AL: "HOCl-Mediated Glycerophosphocholine and Glycerophosphoethanolamine Generation from Plasmalogens in Phospholipid Mixtures", LIPIDS, vol. 45, no. 1, 1 January 2010 (2010-01-01), DE, pages 37 - 51, XP055983122, ISSN: 0024-4201, DOI: 10.1007/s11745-009-3365-8 * |
TANG CHUAN-HO ET AL: "Phosphorylcholine-containing lipid molecular species profiling in biological tissue using a fast HPLC/QqQ-MS method", ANALYTICAL AND BIOANALYTICAL CHEMISTRY, vol. 404, no. 10, 1 December 2012 (2012-12-01), Berlin/Heidelberg, pages 2949 - 2961, XP093000342, ISSN: 1618-2642, Retrieved from the Internet <URL:https://link.springer.com/content/pdf/10.1007/s00216-012-6414-8.pdf> DOI: 10.1007/s00216-012-6414-8 * |
Also Published As
Publication number | Publication date |
---|---|
WO2022263927A2 (en) | 2022-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021000887A (en) | Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer. | |
AR041566A1 (en) | INDOL DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES | |
MX2022005232A (en) | Small molecule degraders of helios and methods of use. | |
CU20210002A7 (en) | DERIVATIVES OF 3- (5-HYDROXY-1-OXOISOINDOLIN-2-IL) PIPERIDINE-2,6-DIONA AND THEIR USE IN THE TREATMENT OF PROTEIN-DEPENDENT DISORDERS WITH ZINC 2 FINGERS OF THE IKAROS FAMILY (IKZF2) | |
MX2007004183A (en) | Benzoimidazole derivatives useful as antiproliferative agents. | |
WO2021133896A8 (en) | Transcriptional enhanced associate domain (tead) transcription factor inhibitors and uses thereof | |
CO2019008531A2 (en) | Atazanavir (ATV) analogs to treat hiv infections. | |
EA200500174A1 (en) | NEW BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS | |
CA3180846A1 (en) | Inhibitors of transcriptional enhanced associate domain (tead) and uses thereof | |
GEP20217242B (en) | Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors | |
EA200500018A1 (en) | BENZONE-CONDENSED HETEROARILAMIDE TYENOPIRIDIN DERIVATIVES USED AS THERAPEUTIC AGENTS, PHARMACEUTICAL COMPOSITIONS, INCLUDING THEM, AND THEIR APPLICATION | |
EA200601350A1 (en) | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL APPLICATIONS | |
GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
MX2021010242A (en) | Jak inhibitor compound and use thereof. | |
MX2022000244A (en) | PYRROLO [2, 3-b] PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF. | |
AR065622A1 (en) | DERIVATIVES OF 3-CIANO -4- (4-PHENYL- PIPERIDIN -1- IL) PIRIDIN -2- ONA | |
HRP20070505A2 (en) | Spiro-oxindole compounds and their uses as therapeutic agents | |
AR044005A1 (en) | BICYCLE COMPOUNDS, PROCEDURE FOR PREPARATION, ITS USE TO PREPARE A MEDICINAL PRODUCT AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM | |
PH12020552017A1 (en) | 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof | |
PH12019550226A1 (en) | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | |
WO2010043953A3 (en) | Novel bridged cyclic compounds as histone deacetylase inhibitors | |
MY183974A (en) | Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation | |
WO2020097400A8 (en) | Imidazopyridine derivatives and aza-imidazopyridine derivatives as janus kinase 2 inhibitors and uses thereof | |
PH12021550958A1 (en) | Trifluoromethyl-substituted sulfonamide as bcl-2-selective inhibitor | |
WO2019099564A8 (en) | Novel imidazopyrimidine compounds and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22748422 Country of ref document: EP Kind code of ref document: A2 |